These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23628473)

  • 21. Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice.
    Chen W; Lai Y; Wang L; Xia Y; Chen W; Zhao X; Yu M; Li Y; Zhang Y; Ye H
    J Diabetes Complications; 2015 Mar; 29(2):164-75. PubMed ID: 25499591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism.
    Yoon M; Jeong S; Nicol CJ; Lee H; Han M; Kim JJ; Seo YJ; Ryu C; Oh GT
    Exp Mol Med; 2002 Dec; 34(6):481-8. PubMed ID: 12526091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice.
    Murru E; Muntoni AL; Manca C; Aroni S; Pistis M; Banni S; Carta G
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
    Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
    Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.
    Panigrahy D; Kaipainen A; Huang S; Butterfield CE; Barnés CM; Fannon M; Laforme AM; Chaponis DM; Folkman J; Kieran MW
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):985-90. PubMed ID: 18199835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PPAR
    Mandala A; Chen WJ; Armstrong A; Malhotra MR; Chavalmane S; McCommis KS; Chen A; Carpenter D; Biswas P; Gnana-Prakasam JP
    Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(4):G262-G269. PubMed ID: 34287090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice.
    Shin Y; Lee M; Lee D; Jang J; Shin SS; Yoon M
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity.
    Ramakrishnan SK; Russo L; Ghanem SS; Patel PR; Oyarce AM; Heinrich G; Najjar SM
    J Biol Chem; 2016 Nov; 291(46):23915-23924. PubMed ID: 27662905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
    Srivastava RA; He S
    Mol Cell Biochem; 2010 Dec; 345(1-2):197-206. PubMed ID: 20740305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.
    Bijland S; Pieterman EJ; Maas AC; van der Hoorn JW; van Erk MJ; van Klinken JB; Havekes LM; van Dijk KW; Princen HM; Rensen PC
    J Biol Chem; 2010 Aug; 285(33):25168-75. PubMed ID: 20501652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice.
    Jeong S; Yoon M
    Exp Mol Med; 2009 Jun; 41(6):397-405. PubMed ID: 19322024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice.
    Chan SM; Zeng XY; Sun RQ; Jo E; Zhou X; Wang H; Li S; Xu A; Watt MJ; Ye JM
    Biochim Biophys Acta; 2015 Jul; 1852(7):1511-9. PubMed ID: 25906681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
    Ernst MC; Sinal CJ; Pollak PT
    Pharmacol Res; 2010 Nov; 62(5):408-15. PubMed ID: 20654716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nutritional background changes the hypolipidemic effects of fenofibrate in Nile tilapia (Oreochromis niloticus).
    Ning LJ; He AY; Lu DL; Li JM; Qiao F; Li DL; Zhang ML; Chen LQ; Du ZY
    Sci Rep; 2017 Jan; 7():41706. PubMed ID: 28139735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
    Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
    Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice.
    Kondo K; Sugioka T; Tsukada K; Aizawa M; Takizawa M; Shimizu K; Morimoto M; Suematsu M; Goda N
    Adv Exp Med Biol; 2010; 662():77-82. PubMed ID: 20204774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats.
    Karakan T; Kerem M; Cindoruk M; Engin D; Alper M; Akın O
    Turk J Gastroenterol; 2013; 24(2):134-40. PubMed ID: 23934460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.
    Kuno T; Hata K; Takamatsu M; Hara A; Hirose Y; Takahashi S; Imaida K; Tanaka T
    Int J Mol Sci; 2014 May; 15(5):9160-72. PubMed ID: 24857924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
    Srivastava RA
    Eur J Pharmacol; 2009 Apr; 607(1-3):258-63. PubMed ID: 19245804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.